Compare Dyne Therapeutics Inc. Common Stock (DYN) vs JFrog Ltd. Ordinary Shares (FROG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs JFrog Ltd. Ordinary Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while JFrog Ltd. Ordinary Shares trades at $91 (market cap $12.24B). The key difference: JFrog Ltd. Ordinary Shares is far larger — about 4.3× Dyne Therapeutics Inc. Common Stock's market cap, and JFrog Ltd. Ordinary Shares is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and JFrog Ltd. Ordinary Shares for 5 Days on average.
| DYN | FROG | |
|---|---|---|
Market Cap | $2.86B | $12.24B |
Volume | 3,341,579 | 1,786,951 |
Sector | Health | Technology |
52-Week High | $26.78 | $104.03 |
52-Week Low | $14.60 | $34.75 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $2.18B | $11.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
JFrog (FROG) trades at $99.28, up 0.26% on the day, showing strong technical momentum with a bullish moving average signal and trading near pivot point resistance at $99. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending, while maintaining robust revenue growth projections from $532M in 2025 to $600M in 2026. Recent product announcements at swampUP 2026 focused on AI-era software supply chain security enhancements.
Wall Street maintains strong bullish sentiment with 87.5% buy ratings and a $110.25 consensus price target, representing 11% upside potential. However, negative profitability metrics and insider selling activity present near-term headwinds. The stock's elevated P/S ratio of 19.77 requires continued execution on growth targets to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About JFrog Ltd. Ordinary Shares
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →
